MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock and...
$259,948K
Proceeds from issuance of
common stock pursuant...
$10,131K
Net cash provided by
financing activities
$270,079K
Net increase
(decrease) in cash, cash...
$28,475K
Canceled cashflow
$241,604K
Fair value of common
stock issued in...
$415,271K
Holdback liabilities
$71,790K
Accounts payable,
accrued expenses and...
$57,244K
Stock-based compensation
$36,202K
Depreciation and
amortization
$6,874K
Unrealized foreign
exchange loss (gain)
-$1,098K
Non-cash lease expense
$550K
Amortization of debt discount
and offering costs
$454K
Proceeds from maturities
of investments
$33,892K
Net cash used in
operating activities
-$228,763K
Net cash used in
investing activities
-$11,569K
Effect of exchange rate
on cash, cash...
-$1,272K
Canceled cashflow
$589,483K
Canceled cashflow
$33,892K
Net loss
-$790,155K
Purchase of investments
$34,797K
Accounts receivable
$12,886K
Prepaid and other
current assets
$6,630K
Other assets
$4,796K
Inventory
$1,920K
Change in fair value of
holdback liabilities
$998K
Operating lease
liabilities
-$583K
Other
$278K
Payments made for
additions to intangible...
$10,000K
Purchase of property and
equipment
$664K
Back
Back
Cash Flow
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)
source: myfinsight.com